Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma by Ferretti, E. et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=koni20
Download by: [Universita di Palermo] Date: 12 October 2016, At: 06:12
OncoImmunology
ISSN: (Print) 2162-402X (Online) Journal homepage: http://www.tandfonline.com/loi/koni20
Interleukin-17A promotes the growth of human
germinal center derived non-Hodgkin B cell
lymphoma
Elisa Ferretti, Emma Di Carlo, Emanuela Ognio, Carla Guarnotta, Francesco
Bertoni, Anna Corcione, Ignazia Prigione, Giulio Fraternali-Orcioni,
Domenico Ribatti, Jean Louis Ravetti, Maurilio Ponzoni, Claudio Tripodo &
Vito Pistoia
To cite this article: Elisa Ferretti, Emma Di Carlo, Emanuela Ognio, Carla Guarnotta, Francesco
Bertoni, Anna Corcione, Ignazia Prigione, Giulio Fraternali-Orcioni, Domenico Ribatti, Jean Louis
Ravetti, Maurilio Ponzoni, Claudio Tripodo & Vito Pistoia (2015) Interleukin-17A promotes the
growth of human germinal center derived non-Hodgkin B cell lymphoma, OncoImmunology,
4:10, e1030560, DOI: 10.1080/2162402X.2015.1030560
To link to this article:  http://dx.doi.org/10.1080/2162402X.2015.1030560
View supplementary material Accepted author version posted online: 19
Jun 2015.
Published online: 19 Jun 2015.
Submit your article to this journal Article views: 86
View related articles View Crossmark data
Interleukin-17A promotes the growth of human
germinal center derived non-Hodgkin B cell
lymphoma
Elisa Ferretti1,*, Emma Di Carlo2, Emanuela Ognio3, Carla Guarnotta4, Francesco Bertoni5, Anna Corcione1, Ignazia Prigione1,
Giulio Fraternali-Orcioni6, Domenico Ribatti7, Jean Louis Ravetti6, Maurilio Ponzoni8, Claudio Tripodo4, and Vito Pistoia1
1Laboratorio di Oncologia; Istituto Giannina Gaslini; Genova, Italia; 2Department of Medicine and Sciences of Aging; “G. d’Annunzio” University and Ce.S.I. Aging Research Center;
“G. d’Annunzio” University Foundation; Chieti, Italy; 3IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro; Genova, Italy; 4Tumor Immunology Unit; Department
of Health Science; Human Pathology Section; University of Palermo; Palermo, Italy; 5Lymphoma & Genomics Research Program; -IOR- Institute of Oncology Research;
and -IOSI- Lymphoma Unit; Oncology Institute of Southern Switzerland; Bellinzona, Switzerland; 6Unit of Pathology; IRCCS AOU San Martino -IST- Istituto Nazionale per la Ricerca
sul Cancro; Genova, Italy; 7Department of Basic Medical Sciences; Neurosciences and Sensory Organs; University of Bari Medical School; Bari; Italy; and National Cancer Institute
“Giovanni Paolo II”; Bari, Italy; 8Pathology Unit; Unit of Lymphoid Malignancies; San Raffaele Scientiﬁc Institute; Milano, Italy
Keywords: angiogenesis, B non-Hodgkin lymphoma, GC B cells, IL-17A, IL-17A receptor, tumor immunology
Abbreviations: Abs, antibodies; B-NHL, B cell non-Hodgkin lymphomas; BL, Burkitt lymphoma; CB, centroblasts; CC, centrocytes;
CAM, Chorioallantoic membrane; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; FITC, Fluorescein 15 Isothio-
cyanate; GC, germinal center; HPSE, Heparan sulfate proteoglycan; ID1, inhibitor of differentiation/DNA binding 1; IGF-1, Insu-
lin-like growth factor 1; IL, Interleukin; LAMA5, Laminin-a5; LECT1, leukocyte cell derived chemotaxin; MRFI, Mean Relative
Fluorescence Intensity; m, monoclonal; NOD, Non Obese Diabetic; p, phosphorylated; PE, Phycoerythrin; PGE, prostaglandin; R,
receptor; rh, recombinant human; SCID, Severe combined immunodeficiency; TGFb-R1, transforming growth factor b receptor 1;
VEGF, vascular growth factor.
Interleukin (IL)-17A belongs to IL-17 superfamily and binds the heterodimeric IL-17 receptor (R)(IL-17RA/IL-17RC).
IL-17A promotes germinal center (GC) formation in mouse models of autoimmune or infectious diseases, but the role of
IL-17A/IL-17AR complex in human neoplastic GC is unknown. In this study, we investigated expression and function of
IL-17A/IL-17AR in the microenvironments of 44 B cell non-Hodgkin lymphomas (B-NHL) of GC origin (15 follicular
lymphomas, 17 diffuse large B cells lymphomas and 12 Burkitt lymphomas) and 12 human tonsil GC. Furthermore, we
investigated the role of IL-17A in two in vivo models of GC B cell lymphoma, generated by s.c. injection of SU-DHL-4 and
OCI-Ly8 cell lines in Severe combined immunodeﬁciency (SCID)/Non Obese Diabetic (NOD) mice. We found that: (i) B-
NHL cell fractions and tonsil GC B cells expressed IL-17RA/IL-17RC, (ii) IL-17A signaled in both cell types through NF-
kBp65, but not p38, ERK-1/2, Akt or NF-kBp50/105, phosphorylation, (iii) IL-17A was expressed in T cells and mast cells
from neoplastic and normal GC microenvironments, (iv) IL-17A rendered tonsil GC B cells competent to migrate to
CXCL12 and CXCL13 by downregulating RGS16 expression; (v) IL-17A stimulated in vitro proliferation of primary B-NHL
cells; (vi) IL-17A (1 mg/mouse-per dose) stimulated B-NHL growth in two in vivo models by enhancing tumor cell
proliferation and neo-angiogenesis. This latter effect depended on IL-17A-mediated induction of pro-angiogenic gene
expression in tumor cells and direct stimulation of endothelial cells. These data deﬁne a previously unrecognized role of
human IL-17A in promoting growth of GC-derived B-NHL and modulating normal GC B cell trafﬁcking.
Introduction
IL-17A belongs to the IL-17 cytokine superfamily together
with five additional structurally related cytokines, namely
IL-17B, IL-17C, IL-17D, IL-17E and IL-17F. IL-17A is synthe-
sized by Th17 cells, gamma-delta T cells, natural killer T cells,
lymphoid tissue-inducer like cells, Paneth cells and neutrophils.1
The biological effects of IL-17 family cytokines are medi-
ated by five different receptor (R) subunits (RA, RB, RC,
RD, RE), that are single transmembrane domain-containing
proteins which can heterodimerize or homodimerize in dif-
ferent combinations.2 The heterodimer formed by IL-17RA
and IL-17RC binds IL-17A, IL-17F and the heterodimeric
cytokine IL-17A/IL-17F. 2,3 IL-17RA is expressed ubiqui-
tously, with high levels in the hematopoietic cell compart-
ment.4,5 IL-17RC is highly expressed in epithelial cells of
prostate, kidney and joints, and at lower levels in hemato-
poietic cells.6
The main physiological function of IL-17A is protection from
bacterial and fungal infections through recruitment of
*Correspondence to: Elisa Ferretti; Email: elisaferretti@ospedale-gaslini.ge.it
Submitted: 01/14/2015; Revised: 03/12/2015; Accepted: 03/13/2015
http://dx.doi.org/10.1080/2162402X.2015.1030560
www.tandfonline.com e1030560-1OncoImmunology
OncoImmunology 4:10, e1030560; October 2015; © 2015 Taylor & Francis Group, LLC
ORIGINAL RESEARCH
neutrophils to the site of inflammation.4,7 In addition, IL-17A
stimulates the production of other cytokines and chemokines
such as G-CSF, IL-6 and IL-8.2 Th17 cell-derived IL-17A enhan-
ces isotype switching in mouse and human B cells 8 and is
involved in the pathogenesis of several autoimmune and allergic
diseases. 4 In this respect, IL-17A was found to promote GC for-
mation in different mouse models of human autoimmune or
infectious diseases 8-11 via specific signaling pathways.12
In this study, we have addressed IL-17AR expression and IL-
17A activity on malignant B cells isolated from lymph node
biopsies of patients with B-NHL of GC origin, namely follicular
lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and
Burkitt lymphoma (BL). In addition, we have investigated
expression and function of IL-17AR on human tonsil GC B cells
and of IL-17A in the GC microenvironment.
BL and DLBCL are tumors with predominant centroblastic
morphology, while FL contains centrocytic and centroblastic
components in different ratios depending on tumor grade.13,14
BL and DLBCL are highly proliferating tumors that invade the
GC and quickly replace the physiological microenvironment. In
contrast, FL displays a follicular growth pattern that is partially
retained for a long time over the natural history of the dis-
ease.13,14 Both DLBCL and FL occur commonly in adults and
rarely in children or adolescents.15 DLBCL is the most frequent
B-NHL subtype, with approximately one third of cases originat-
ing from the transformation of FL.14 BL affects predominantly
children or young adults, with frequent intra-abdominal or extra-
nodal involvement.15
We show that IL-17A promotes the growth of B-NHL both
in vitro and in vivo by stimulating tumor cell proliferation and
neo-angiogenesis. In contrast, IL-17A does not affect prolifera-
tion or survival of freshly isolated normal GC B cells, but renders
them competent to migrate to CXCL12 and CXCL13 through
an NF-kBp65-dependent mechanism, thus contributing to regu-
late the trafficking of these cells within the GC.
Results
Expression of IL-17AR in human B-NHL lymph node and
tonsil germinal center
Both IL-17RA and IL-17RC mRNAs were detected at com-
parable levels in FL, DLBCL and BL samples (Fig. 1A). Expres-
sion of IL-17RA and IL-17RC on the surface of primary
neoplastic cells was detected by flow cytometry in 24 lymph node
samples of GC-derived B cell lymphoma. In particular, Fig. 1B
shows the results obtained with 9 FL, 11 DLCBL and 4 BL cases.
The insets in Fig. 1B show a representative staining for IL-17RA
and IL-17RC in a FL, BL and DLBCL case, respectively (Mean
Relative Fluorescence Intensity (MRFI) § SD for FL: IL17RA D
3.1 § 1.5 and IL-17RC D 2.5 § 0.5; MRFI § SD for DLBCL:
IL17RA D 2.5 § 1.2 and IL-17RC D 2.2 § 1.5; MRFI § SD
for BL: IL17RA D 2.8 § 0.8 and IL-17RC D 2.3 § 1.5).
IL-17RA and IL-17RC expression was next assessed by flow
cytometry in different GC B cell subsets freshly isolated from six
tonsils. GC B cells (CD38high, CD39¡ IgD¡), were found to
express IL-17RA and IL-17RC (Fig. 1C). The insets in Fig. 1C
show a representative staining of GC B cells for IL-17RA and IL-
17RC (MRFI § SD for GC B cells: IL17RA D 3.7 § 1.7 and
IL-17RCD2.5 § 0.9). Moreover, both centrocytes (CC,
CD38dim CD77¡ B cells) and centroblasts (CB, CD38high
CD77C B cells) were found to express IL-17RA and IL-17RC
(MRFI § SD for CB : IL-17RAD 3.2 § 1.4 and IL-17RCD 2.4
§ 0.6; MRFI § SD for CC: IL-17RA D 3.4 § 1.6 and
IL-17RCD 2.1 § 0.7).
IL-17AR function in human normal and malignant
GC B cells
IL-17A activates the canonical NF-kB signaling pathway in
different cell types.12 As shown in Fig. 2A (upper panel), IL-
17A upregulated significantly phosphorylated (p)NF-kBp65,
but not NF-kBp65 (similar levels of about 95 § 3% of expres-
sion in treated and untreated cells), in primary B-NHL cells
upon incubation for 1 to 30 min with recombinant human (rh)
IL-17A, with a peak at 1 min (p D 0,003 for three FL and three
DLBCL samples). Likewise, a significant upregulation of pNF-
kBp65, but not NF-kBp65 (similar levels of about 93 § 2% of
expression in treated and untreated cells), was observed in four
tonsil GC B cell suspensions after 10 and 30 min culture with
IL-17A (p D 0,01 and D 0,002, respectively), as assessed by flow
cytometry (Fig. 2A, lower panels). The faster kinetics of NF-
kBp65 phosphorylation in malignant B cells vs. their normal
counterparts may depend on intrinsic characteristics of the for-
mer cells due to their transformed state. In contrast, IL-17A did
not induce phosphorylation of NF-kB p50/105, 12 or of p-38,
ERK1/2, AKT, JNK in either malignant or normal GC B
cells.12,16
IL-17A, as well as CD40L tested as positive control, 17 signifi-
cantly increased proliferation of tumor cells over background lev-
els: p D 0,01 and p D 0.009 for five FL samples (Fig. 2B left
panel) and p D 0, 009 and p D 0.01 for four DLBCL samples
(Fig. 2B right panel), respectively. No direct effect of IL-17A on
survival or migration of B-NHL cells was observed following co-
stimulation with CD40L or anti-IgM/IgG tested alone or in
combination (data not shown). For in vitro functional experi-
ments, we tested FL and DLBCL as model of GC-derived
B-NHL since the number of cases of these lymphomas was much
higher than that of BL.
In contrast, IL-17A did not rescue normal GC B cells from
apoptosis nor did it increase the rate of survival induced by
rhCD40L stimulation at any time tested (Fig. S1A). Likewise,
IL-17A did not affect proliferation of GC B cells either in the
presence or absence of rhCD40L (Fig. S1B),18 nor was chemo-
tactic for the latter cells (Fig. S1C).
IL-17A confers migratory competence to CXCL12 and
CXCL13 on tonsil GC B cells
We next asked whether IL-17A could modulate CXCR4 and
CXCR5 expression and/or function in tonsil GC B cells, thus
impacting on their migration within the GC.19 The latter cells,
freshly isolated from eight different tonsil samples were pre-incu-
bated for 3 or 6 h with or without 20 ng/mL rhIL-17A, and
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subjected to chemotaxis in response to CXCL12 or CXCL13.
The proportions of apoptotic GC B cells after 3 and 6 h culture
were on average 12 and 22%, respectively, as assessed by Annexin
V staining, irrespective of they had been exposed or not to IL-
17A. The poor viability of GC B cells is a well-known feature of
this cell population.20
Treatment of GC B cells with IL-17A for 3 or 6 h induced
their de novo chemotaxis to 300 ng/mL CXCL12 or CXCL13 (p
D 0.0005 and p D 0.0007, respectively at both times tested),
whereas GC B cells pre-incubated with medium alone never
migrated to either chemokine (Fig. 3A).21 Likewise, GC B cells
pre-incubated with rhCD40L were attracted by CXCL1222 or
CXCL13 (Fig. 3A). The ratio between CB and CC in migrated
cells upon stimulation with IL-17A or CD40L was similar to
that detected in the same cell fractions before being tested, indi-
cating that CB and CC were equally attracted by both chemo-
kines. Incubation of GC B cells with either rhIL-17A or
rhCD40L did not change the MRFI (Fig. 3B) or the percentage
of CXCR4C or CXCR5C GC B cells (median for CXCR4 of 89
§ 5 % and for CXCR5 of 92 § 7 % with or without the treat-
ment with rhIL-17A or rhCD40L). Therefore, we tested whether
IL-17A driven acquisition of migratory competence to CXCL12
Figure 1. Expression of IL-17A receptor in primary tumor cells from patients with FL, DLBCL or BL and in their normal counterpart. (A) Expression levels of
IL-17RA and IL-17RC in FL, DLBCL and BL, as measured using the Affymetrix GeneChip U133 array. Data obtained from the GSE16131 (FL) 48 and GSE4475
(DLBCL, BL) 47 datasets, both produced using the Affymetrix U133A. The line in the middle of the box-plot represents the median and the box extends
from the 25th to the 75th percentile (interquartile range, IQ); the whiskers extend to the upper and lower adjacent values (i.e., §1.5 IQ); outside values
are individually plotted. Y-axis, expression values (RMA, Robust Multiarray Average). (B) Neoplastic B cells were stained with anti-k or anti-lmAbs in com-
bination with anti-IL-17RA or anti-IL-17RC mAbs and analyzed by ﬂow cytometry. Results for 9 FL, 11 DLCBL and 4 BL are shown in box plot, as median %
positive cells, maximum, minimum and ﬁrst and third quartile. Insets. A representative staining for IL-17RA and IL-17RC in FL, DLBCL and BL is shown, as
assessed by ﬂow cytometry. Dark gray histogram: isotype control. Gray histogram: receptor staining. In the plot mean of mean relative ﬂuorescence
intensity (MRFI) § SD is reported. (C) Freshly isolated tonsil MNC were stained with CD38, CD39 or anti-IgD mAbs in combination with anti-IL-17RA or
anti-IL-17RC mAbs and analyzed by ﬂow cytometry. Results are mean % positive cells C SD in GC B cells subset (N D 6). Insets. A representative staining
for IL-17RA and IL-17RC in tonsil GC is shown, as assessed by ﬂow cytometry. Gray histogram: isotype control. Dark gray histogram: receptor staining. In
the plot mean of MRFI § SD is reported.
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and CXCL13 by tonsil GC B cells was related to downregulation
of RGS16, a negative controller of signaling through these che-
mokine receptors. 23 Indeed, treatment of GC B cells with rhIL-
17A or rhCD40L, but not with IFNg tested as negative
control, caused significant downregulation of RGS16 expression
(p D 0 .005 for rhIL-17A and p D 0.002 for rhCD40L)
(Fig. 3C).
Consistent with previous studies, freshly isolated B-NHL cells
of GC origin (five FL and four DLCBL samples) expressed
CXCR4 and CXCR5 at levels comparable to those detected in
normal GC B cells and migrated to CXCL12 and CXCL13.22
Treatment of B-NHL cells with 20–50 ng/mL rhIL-17A in com-
bination or not with CD40L and/or anti-IgM/IgG did not
enhance chemotaxis to either chemokine or expression of the
respective receptors CXCR4 and CXCR5 (not shown) nor mod-







neoplastic and normal GC
B cells after IL-17RA




in both cell types following
blocking with IL-17RA
mAb, but not with control
mAb (Figs. 4A and 5A).
Accordingly, IL-17A
induced proliferation of
primary B-NHL cells (two
FL and three DLCBL) was
abrogated by pre-treatment
of cells with the former,
but not the latter, mAb
(Fig. 4B). Finally, blocking
of IL-17RA abolished IL-
17A-induced chemotaxis of
tonsil GC B cells to
CXCL12 and CXCL13
(Fig. 5B) and downregula-
tion of RGS16 expression
in the same cells (Fig. 5C).
In contrast, RGS16 down-
regulation induced by cul-
ture of tonsil GC B cells
with CD40L was unaf-





17AR in the functional activities of the cytokine in malignant
and tonsil GC B cells here reported.
IL-17A expression in normal and neoplastic germinal
center microenvironments
Immunofluorescence analysis of tonsil tissue sections revealed
that IL-17A was predominantly expressed within para-follicular
T cell-rich areas where it marked scattered cells with a monocy-
toid morphology consistent with activated T cells and/or myeloid
cells. Double-marker immunofluorescence analysis showed that
most IL-17A-positive cells were CD3C T cells admixed with rare
TryptaseC mast cells (Fig. 6A, B). No CD20C B cells expressing
IL-17A were detected. In B-NHL samples the expression of IL-
17A was restricted to scattered reactive CD3C T cells and occa-
sional TryptaseC mast cells (Fig. 6C–H).
Figure 2. IL-17A signaling and function in tonsil and neoplastic GC (B)cells. (A) Upper panel: Flow cytometric analy-
sis of pNF-kBp65 in neoplastic cells from three FL (left panel) or three DLBCL (right panel) treated for 0, 1, 10, 30 or
60 min with IL-17A. Results are shown as mean % positive cells C SD. White histograms: medium alone. Gray histo-
grams: cells stimulated with rhIL-17A. Lower panel: analysis of pNF-kBp65 in isolated GC B cells stimulated for 0, 1,
10, 30 and 60 min with rhIL-17A, as assessed by ﬂow cytometry. Results are mean % positive cells C SD of four sam-
ple tested. White histograms: medium alone. Gray histograms: cells stimulated with rhIL-17A. (B) Primary neoplastic
cells from patients with ﬁve FL (left panel) and four DLBCL (right panel) were cultured without (Med) or with rhIL-
17A or rhCD40L and tested for proliferation by 3H-TdR incorporation. The results shown refer to experiments per-
formed with 20 ng/mL IL-17A, but stimulation of lymphoma cell proliferation was signiﬁcant also at 10 and
50 ng/mL IL-17A. Results are expressed in box plot, as median % positive cells, maximum, minimum and ﬁrst and
third quartile.
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Expression and function
of IL-17AR in GC derived
B-NHL cell lines
Five different malignant
cell lines derived from GC B-
NHL, i.e., SU-DHL-4,
DoHH2, OCI-Ly8, Raji and
Ramos, were next tested for
IL-17AR expression and
functionality. As shown in
Fig. S2A, all cell lines
expressed both IL-17AR sub-
units, as assessed by flow
cytometry. Similarly to pri-
mary lymphoma cells, a
significantly increased pNF-
kBp65 was detected in all cell
lines incubated with 20 ng/
mL rhIL-17A compared to
cells incubated with medium
alone. Fig. S2D shows
experiments performed with
the SU-DHL-4 and OCI-
Ly8 cell lines, in which pNF-
kBp65 increased significantly
over background levels at 10
and remain significant at 600.
These cell lines were selected
for the following in vivo
experiments.
In vivo effects of IL-
17A on B-NHL growth
The tumorigenicity of
SU-DHL-4 and Oci-Ly8
cells injected in SCID-
NOD mice by different
routes of inoculation (i.p.,
i.v. and s.c.) was tested in
order to develop a model
suitable for the investiga-
tion of the in vivo effects of
hrIL-17A. The best rate of
growth was observed when
neoplastic cells were
injected s.c., allowing for-
mation of masses easy to
isolate and analyze. Thus,
we inoculated 5 £ 106 SU-
DHL-4 or Oci-Ly8 cells
s.c. into 30 NOD/SCID
mice. The mice were sepa-
rated in two groups and
treated with 3 weekly doses
of rhIL-17A (1 mg/doses),
or PBS (controls) for 20 d
Figure 3. Effects of IL-17A receptor triggering in human freshly isolated tonsil (B)cells. (A) 5 £ 106 freshly isolated
GC B cells were treated for 6 h without (Med) or with rhIL-17A or rhCD40L and subjected to chemotaxis to 300 ng/
mL CXCL12 or CXCL13. Results are shown as mean number of migrated cells C SD of eight sample analyzed. (B)
Expression of CXCR4 and CXCR5 in GC B cells treated for 6 h without (Med) or with rhIL-17A or rhCD40L. Results are
MRFI C SD of eight sample tested. (C) Intracellular expression of RGS-16 in freshly isolated GC B cells treated for 6 h
with or without (Med) rhIL-17A, rhCD40L or IFNg, as assessed by ﬂow cytometry. Results are mean percent positive
cells C SD of eight sample tested.
Figure 4. Effects of IL-17RA blocking on IL-17 mediated signaling in neoplastic cells and related functional activities.
(A) Flow cytometric analysis of pNFkBp65 in neoplastic cells from neoplastic GC B cells (two FL and three DLCBL) pre-
incubated with IL-17RA blocking mAb, or control mAb, and treated for 0, 10 or 30 min with rhIL-17A. Results are
shown as mean % positive cells C SD. (B) Primary neoplastic cells (two FL and three DLCBL) were pre-incubated with
IL-17RA blocking mAb, or control mAb, cultured without (Med) or with rhIL-17A and tested for proliferation by 3H-
TdR incorporation. Results are expressed in box plot, as median % positive cells, maximum, minimum and ﬁrst and
third quartile.
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The size of tumors formed by SU-DHL-4 cells (Fig. 7A) or Oci-
Ly8 cells (Fig. S3) was significantly increased in IL-17A treated
vs. untreated mice (p D 0, 0131 and 0.04, respectively), indicat-
ing that the cytokine stimulated B-NHL growth. The animals
did not show any evidence for increased size of internal organs
(spleen, liver, lymph nodes, lung, kidney, brain), irrespective of
whether they had received IL-17A or PBS, making it unlikely
that IL-17A could promote tumor metastasis.
Histological and immunohistochemical studies carried out on
lymphoid tumor masses formed by SU-DHL-4 (Fig. 7B) or
Oci-Ly8 cells (not shown) provided similar results. Tumors from
PBS treated SCID/NOD mice showed a few, but clearly detect-
able, apoptotic events (as assessed by TUNEL assay) and a dis-
tinct microvascular supply (as assessed by laminin and CD31
staining) (Fig. 7B, panels A–D, and Table 1). Treatment with
rhIL-17A reduced the frequency of apoptotic events and clearly
increased microvascular network development (Fig. 7B, panels
E–H). Flow cytometric analysis of cell suspensions from
explanted tumors revealed significantly (p D 0,0087) increased
proportions of Ki-67C pro-
liferating cells in mice
treated with IL-17A vs. PBS
(Fig. 7C).
Human angiogenesis
PCR array experiments per-
formed with SU-DHL-4
tumors from 4 rhIL-17A
treated mice in comparison
to tumors from four PBS-
treated mice showed that
17A treatment upregulated
mRNA expression of the
pro-angiogenic genes Hep-
aran sulfate proteoglycan
(HPSE), inhibitor of differ-
entiation/DNA binding 1
(ID1), leukocyte cell derived
chemotaxin (LECT1), IL-
1B, and Laminin-a 5
(LAMA5) and downregu-
lated expression of two addi-
tional pro-angiogenic genes,
namely Insulin-like growth
factor 1 (IGF-1) and trans-





with rhIL-17A for 12 d
resulted in a significant
angiogenic response in the
form of numerous allantoic
neovessels developing radi-
ally toward the implant
in a ‘spoked-wheel’ pattern
(mean number of vessels D 26 § 2 for hrIL-17A) (Fig. 7E, panel
B). Such response was comparable to that induced by vascular
growth factor (VEGF)-A tested as positive control (mean number
of vesselsD 24§ 3) (Fig. 7E, panel C). Negative control incubated
with PBS was devoid of any pro-angiogenic activity (mean number
of vessels D 7 § 1) (Fig. 7E, panel A). These results provide dem-
onstration of the direct pro-angiogenic activity of IL-17A.
Discussion
The GC is a specialized microenvironment formed by prolifer-
ating B cells in the follicles of secondary lymphoid organs during
T cell-dependent antibody responses to exogenous antigens.24
The GC dark zone is enriched in proliferating CB that undergo
somatic hypermutation of the Ig V region genes resulting into
diversification of the IgV repertoire. Thereafter, CB migrate to
the light zone where they transform into CC, a minority of which
is selected to survive, undergoes Ig isotype switch and
Figure 5. Effects of IL-17RA blocking on IL-17 mediated signaling in normal GC (B)cells and related functional activi-
ties. (A) Flow cytometric analysis of pNFkBp65 in tonsil GC B cells (n D 5) pre-incubated with IL-17RA blocking mAb,
or control mAb, and treated for 0, 10 or 30 min with rhIL-17A. Results are shown as mean % positive cells C SD. (B)
Freshly isolated tonsil GC B cells were pre-incubated with IL-17RA blocking mAb, or control mAb, and then treated
for 6 h without (Med) or with rhIL-17A and subjected to chemotaxis to 300 ng/mL CXCL12 or CXCL13. Results are
shown as mean number of migrated cells C SD. (C) Intracellular expression of RGS-16 in freshly isolated tonsil GC B
cells pre-incubated with IL-17RA blocking mAb and treated for 6 h with or without (Med) rhIL-17A or rhCD40L, as
assessed by ﬂow cytometry. Results are mean percent positive cells C SD.
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Figure 6. Expression of IL-17A in normal and neoplastic GC microenvironment. (A–H) Double-marker immunoﬂuorescence analysis of IL-17AC cells
within reactive tonsil tissue, and in the neoplastic inﬁltrates of FL, DLBCL, and BL samples. Most of the IL-17AC (green) cells co-express (yellow) the T-cell
marker CD3 (red) (panel A–C–E–G), which indicates their T-cell nature. In the same cases, scanty IL-17A-expressing (green) tryptaseC (red) mast cells are
also found (yellow, panel B–D–F–H). Pictures are relative to full sections of 4 representative cases out of the 26 analyzed. Original magniﬁcation, £400.
Double-staining yellow cells are highlighted in an inset present in all panels (A–H) of the Figure. Magniﬁcation, £630. Data were analyzed under a Leica
DM3000 optical microscope and captions were collected using a Leica DFC320 digital camera (Leica).
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differentiates extrafollicularly into memory B cells or long-lived
plasma cells.24 CB express CXCR4 and are attracted to the dark
zone by CXCL12 produced by stromal cells, CC express CXCR5
and are recruited to the light zone along a gradient of CXCL13
produced by FDC.19 Therefore, CXCL12 and CXCL13 play
crucial roles in the regulation of GC B cell trafficking.
Many molecules are involved in GC formation.13,19 IL-17A
represents a recent addition to such list since it promoted GC
formation in a few mouse models of human autoimmune or
infectious diseases.8–12 Furthermore, IL-17A was found to induce
Ig class switching in vitro in mouse and human B cells.25,26 So
far, little is known on IL-17A in relation to human normal or
malignant GC B cell microenvironments.27,28
Variable IL-17A expression was previously detected in lymph
nodes and spleen from CLL patients, where IL-17A producing
cells were identified as Th17 cells, mastocytes and immature
Figure 7. Role of IL-17A on in
vivo tumor growth and angio-
genesis. (A) Volume of tumors
grown s.c. in PBS or IL-17A
treated mice 20 d after SU-
DHL-4 cell injection. Results are
expressed in box plot, as
median % positive cells, maxi-
mum, minimum and ﬁrst and
third quartile (N D 30). (B)
Tumors developed after s.c.
injection of SU-DHL-4 cells in
PBS-treated SCID/NOD mice
are formed by a mixture of
small and large lymphoid cells
with centrocytes and centro-
blasts morphology (A). These
tumors display some apoptotic
events (tunel assay (B)) and a
distinct microvascular network
(laminin immunostaining (C)
and CD31 staining (D)). The his-
tologic features of SU-DHL-4
tumors are not substantially
altered by rhIL-17-A treatment
(E), while apoptotic events
appears less frequent (F) and
the microvascular supply is
clearly more developed (G–H),
particularly at the tumor edge,
in comparison with control
tumors. (C) Flow cytometric
analysis of cell proliferation in
cell suspensions from
explanted SU-DHL-4 cell
tumors, as assessed by Ki67
staining. Results for eight PBS
and eight IL-17A-treated mice
are expressed as mean % posi-
tive cells C SD. (D) Gene
expression proﬁling of human
angiogenesis related genes in
SU-DHL-4 tumors explanted
from SCID/NOD mice as
assessed by PCR Array. Results
represent fold differences in
individual mRNA expression
between IL-17A or PBS treated
mice. Pooled results from four
different experiments are
shown. (E) Angiogenic activity
of IL-17A (B), as assessed CAM
assay. PBS (A) and VEGF (C)
were used as negative or posi-
tive control, respectively.
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myeloid cells.27 In another study, in vitro expanded T cells from
lymph nodes of B-NHL patients were found to contain scanty
Th17 cells.27,28
The role of IL-17A and of Th17 cells in tumor growth is con-
troversial. IL-17A is released in the tumor microenvironment of
human cervical malignancies, non-small cell lung carcinoma,
hepatocellular carcinoma and multiple myeloma, for which the
cytokine was found to enhance tumor growth.29-33 In contrast,
IL-17A was shown to inhibit indirectly the growth of mouse mas-
tocytoma and plasmocytoma through T-cell-dependent mecha-
nisms.34 Th17 related IL-21 may counteract tumor progression
in primary B-NHL with ocular localization.35 Moreover, elevated
levels of circulating Th17 cells in CLL correlated with better
prognosis and longer survival. 27
In this study, we have investigated the effects of IL-17A on B
cells from B-NHL of GC origin and their normal counterparts, i.e.,
GC B cells. We demonstrated that IL-17RA and IL-17RC were
expressed in normal and neoplastic GC B cells, and the heterodi-
meric IL-17AR signaled exclusively through the canonical NF-kB
pathway by phosphorylating NF-kBp65 in both cell types, as previ-
ously shown in other cellular models.12,16,36 Neoplastic B cells
from FL, DLBCL and BL proliferated in vitro in response to IL-
17A, suggesting a tumor promoting function of the cytokine. IL-
17A-driven cell signaling and proliferation of B-NHL lymphoma
cells were abrogated by blocking of IL-17AR with a specific mAb.
Since IL-17A expression was detected in CD3C T cells and
occasional tryptase-positive mast cells present in B-NHL micro-
environment, 27 we next investigated the in vivo effects of IL-17A
on the growth of human SU-DHL-4 and Oci-Ly8 DLBCL cells,
tested as models of B-NHL cells. IL-17A increased tumor growth
in SCID/NOD mice by enhancing significantly malignant cell
proliferation and neo-angiogenesis. Human angiogenesis PCR
array analyses revealed upregulation of different pro-angiogenic
genes in explanted tumors from IL-17A vs. PBS-treated mice,
including: HPSE, associated with metastatic cancer;37 ID-1, pro-
moting angiogenesis in normal and cancer cells;38 IL-1B, encod-
ing a pro-inflammatory cytokine broadly involved in the
pathogenesis of cancers;39 LECT1 and LAMA-5, two pro-angio-
genic genes with a poorly understood role in cancer. In contrast
IGF1 and TGFBR1, two additional pro-angiogenic genes, were
downregulated in IL-17A-treated mice, possibly witnessing an
attempt of malignant cells to limit up-regulation of pro-angio-
genic molecule expression. We also performed experiments (not
shown) in which tumors explanted from mice were subjected to
mouse angiogenesis PCR array analysis. In these experiments, no
modulation of gene expression was detected in tumors from IL-
17A treated vs. control mice, indicating that the stimulation of
tumor angiogenesis observed in the former mice depended on
the direct activity of the cytokine on human lymphoma cells.
Different studies have demonstrated the importance of neo-
angiogenesis among the pro-tumoral effects of IL-17A,29,30
highlighting the ability of the cytokine to promote neo-vessel for-
mation through direct and indirect mechanisms. Thus, IL-17A
stimulated migration of vascular endothelial cells 29 and induced
fibroblasts and tumor cells to produce pro-angiogenic growth fac-
tors and cytokines, such as prostaglandin (PGE)1, PGE2, VEGF,
keratinocyte-derived chemokine or macrophage inflammatory
protein-2.29 In a human non-small cell lung cancer model,
IL-17A increased in vivo tumor growth and angiogenesis via a
CXCR2-dependent mechanism.30
Here we show that hrIL-17A had an intrinsic direct pro-angio-
genic activity, as assessed by the ability of the cytokine to stimu-
late new vessel formation in the CAM assay. It is conceivable that
in our experiments the intrinsic pro-angiogenic activity of IL-17A
was a major player in the enhancement of tumor angiogenesis
since expression of a relatively limited number of pro-angiogenic
genes was disclosed in tumor masses by PCR-array experiments.
At variance with that observed with B-NHL cells, IL-17A did
not influence proliferation of normal tonsil GC B cells, possibly
due to intrinsic proneness of these cells to apoptosis and the
inability of IL-17A to counteract this latter process.
We have previously shown that freshly isolated human GC B
cells do not migrate to CXCL12 although they express CXCR4. 40
Nonetheless, incubation of the latter cells with CD40L was found
to render them competent to migrate to CXCL12.40 In the present
study, pre-incubation of human GC B cells with IL-17A conferred
on the latter cells the capacity to migrate to CXCL12 and CXCL13
in the absence of CD40L stimulation. The mechanism underlying
such effects was found to be related to downregulation of RGS16
expression operated by both IL-17A or CD40L, highlighting a
commonmechanism for these molecules.
Detection of IL-17A expressing cells with a predominant
localization in the para-follicular T cell-rich areas of tonsil GC,
expression of IL-17A receptor by GC B cells, and IL-17A-medi-
ated induction of migratory competence to CXCL12 and
CXCL13 in GC B cells all point to IL-17A as a previously
unknown regulator of B cell trafficking in the GC of secondary
lymphoid organs. Our results are consistent with the demonstra-
tion of a role of IL-17A in the development of GC in an autoim-
mune mouse model.10,12 Although RGS16 was found also in the
latter studies to be target of IL-17A activity, the final result of
this molecular interaction was an increased spontaneous GC for-
mation mediated by abolished B cell chemotaxis to CXCL12 and
enhanced retention of GC B cells in the GC.10,12 The reasons for
the discrepancy between the latter results and our findings may
be related to the different experimental models (man vs. mouse
Table 1. Immunohistochemical assessment of microvessels and apoptotic




Microvessels 8.4 § 2.5 14.9 § 3.0*
Apoptotic index % 15.7 § 5.0 6.2 § 3.2*
Apoptotic cell and microvessel count was performed as reported in Meth-
ods. Eight ﬁelds were examined for each tumor section and three sections
per tumor (three cytokine treated vs. three PBS treated) were evaluated.
Results are expressed as mean § SD of TUNEL positive cells/number of total
cells (£600) or, CD31 positive vessels per ﬁeld (£400) evaluated on forma-
lin-ﬁxed sections by immunohistochemistry.
*Values signiﬁcantly different (p <0.05) from corresponding values in
tumors developed in PBS-treated mice.
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and in vitro vs. in vivo studies) and to the strong inflammatory
environment associated with mouse autoimmunity compared
that of human tonsil.
In conclusion, this study delineates previously unrecognized
roles of IL-17A in neoplastic and normal GC. In the latter con-
text, IL-17A unambiguously promotes the growth of human
B-NHL by enhancing tumor cell proliferation and neo-angiogen-
esis, paving the way to future studies addressing the IL-17A/IL-
17AR complex as potential therapeutic target. On the other
hand, IL-17A appears to participate in the regulation of GC B
cell chemotaxis in the normal GC microenvironment.
Materials and Methods
Patients and controls
Heavily infiltrated lymph nodes from patients with FL (n D
15; 9 males and 6 females, age range: 46–61), DLBCL (nD17, 9
males and 8 females, age range: 49–65) and BL (n D 12, 8 males
and 4 female, age range: 7–18), biopsied for diagnostic purposes,
were obtained after informed consent in accordance with the
Declaration of Helsinki. Diagnosis of FL, DLBCL and BL was
established according to the criteria of the Revised European–
American Classification of Lymphoid Neoplasms.15,34 All
patients were studied at diagnosis and were untreated. Twelve
tonsils, surgically removed due to localized inflammation, were
obtained after informed consent. The study was approved by
the Institutional Review Board of Istituto Giannina Gaslini,
Genova, Italy on October 27th, 2005.
Cell isolation and culture
Tonsil B cells (>95 % CD19C cells) were isolated as
reported 41 and enriched for GC B cells ( > 95% CD19C,
CD38high, CD10C, CD44¡ cells) by centrifugation on a dis-
continuous (60–30%) Percoll (Pharmacia) density gradient 41
followed by depletion of CD39C na€ıve and memory B cells.
For in vitro experiments, we used either freshly isolated or fro-
zen tonsil B cells obtaining superimposable results. The latter
cells were cryopreserved in freezing solution containing 50%
RPMI 1640 (Sigma Chemical Company), 40% FBS (Sigma),
and 10% DMSO (Sigma).
Malignant B cell suspensions ( >80–85% CD19C cells) were
first isolated from lymph nodes as reported,22 then cryopreserved
in freezing solution and further enriched (at least 96%) after
thawing by removing (i) residual normal B cells according to the
expression of the Immunoglobulin light chain not expressed by
the malignant clone and (ii) other contaminant cell types (i.e.,
CD3C, CD56C and CD14C cells), through immunomagnetic
bead manipulation (Miltenyi, Miltenyi Biotec). The human SU-
DHL-4 (of DLBCL origin),42 DoHH2 (of FL origin)43 and Raji
and Ramos (of BL origin)44 were used, together with the Oci-
Ly8 cell line that is considered with a DLCBL origin. All cell
lines were provided 2 yr ago by Interlab Cell Line Collection
(Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy) that
certifies their origin by multiplex short tandem repeat profiling.
These cell lines, that were revalidated 4 months ago by Interlab
using the same assay, were cultured in RPMI 1640 medium
(Sigma) supplemented with 10% FBS (Sigma).
Antibodies and flow cytometry
The following mAbs were used: Phycoerythrin (PE)-conju-
gated anti-IL-17RA, Alexa Fluor 488 anti-IL-17RC (R&D Sys-
tem Inc.); PE or Fluorescein Isothiocyanate (FITC) anti-k and
anti-l Ig light chains, PE-CD10 (R&D System); unconjugated-
CD39 (Immunotech); PC7-CD19, PC5-CD38, FITC-CD44,
PC5 and FITC-CD3 (Beckman Coulter); FITC-anti human
Ki67 (DAKO); PE or FITC anti-IgD (Biolegend). PeCy7-CD39
and FITC-CD68 were from eBiosciences (eBiosciences). Anti-
human RGS-16 unconjugated mAb was from Abcam (Abcam).
For intracellular flow cytometry detection, cells were stained with
anti-Ki67 or anti-RGS16 using cytofix/cytoperm kit (Becton-
Dickinson). Cells were stained with fluorochrome-conjugated
mAbs, or unconjugated mAbs followed by fluorochrome-conju-
gated secondary reagents, or with isotype- and fluorochrome-
matched control antibodies. Cells were run on a Gallios
instrument (Beckman Coulter) and data were analyzed using the
Kaluza software (Beckman Coulter). Data were expressed as per-
centage of positive cells or MRFI, calculated as follows: fluores-
cence intensity obtained with specific mAb/fluorescence intensity
obtained with irrelevant isotype-matched mAb. For cytofluori-
metric analysis of tonsil mononuclear cells, we first gated the
lymphocyte population based upon physical parameters and then
gated lymphocytes stained with a specific mAb, e.g., CD19.
Cell signaling
NF-kBp65 (Ser536) phosphorylation was investigated by flow
cytometry.45 Cells were treated for 0–1–5–10–30–60 min with
or without (medium) 20 ng/ml rhIL-17A and stained with an
Alexa 488-conjugated anti-pNF-kBp65 mAb (Cell Signaling
Technology) and an unconjugated anti-NF-kBp65 polyclonal
Ab (Cell Signaling Technology) according to the instructions of
the manufacturer. In brief, cultured cells were collected, fixed
with 2% paraformaldeheyde for 10 min at 37C, incubated with
90% ice-cold methanol for 30 min to permeabilize the cells, and
subsequently stained with the specific Ab for 1h at room temper-
ature. The same protocol was used to investigate the phosphory-
lation of NF-kBp105, ERK1/2, Akt, JNK (Cell Signaling
Technology). Cells were washed and run on Gallios cytometer.
Data were analyzed using the Kaluza software.
Cell proliferation, apoptosis and chemotaxis
Normal and neoplastic cells were analyzed for proliferation
and apoptosis in presence or absence of 10–20–50-ng/mL
rhIL-17A (see the Supplemental Methods). Chemotaxis was
investigated using 5 mm pore-size transwell plates (Costar) as
reported 41 (see the Supplemental Methods).
Blocking experiments
Normal and neoplastic B cells were pre-incubated for 20 min
with 2 mg/mL of an IgG1 blocking mouse mAb to human
IL-17RA (R&D System, clone#133617) or of mouse IgG1 con-
trol mAb (R&D System) at 37C. Thereafter, cells were cultured
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with 50 ng/mL rhIL-17A for different times and subjected to
functional tests.
Immunofluorescence
Tissue samples selected for immunofluorescent analyses were
retrieved from the archives of the Human Pathology Section,
Department of Health Sciences, University of Palermo. Formalin-
fixed and paraffin-embedded tissue sections from six FL, six
DLBCL and eight BL lymph nodes, as well as from six tonsils with
reactive follicular hyperplasia were tested. The immunofluores-
cence techniques are detailed in the Supplemental Methods online.
Gene expression profiling
Raw expression profiles (CEL files) were downloaded from
three publicly available data-sets (GSE2350,46 GSE4475,47
GSE16131)48 and individually imported and normalized using
RMA (Robust Multiarray Average) algorithm in Partek Geno-
mics Suite 6.4 (Partek, St. Louis, MO, USA). Box-plots were cre-
ated with Stata/SE v.12.1 (StataCorp, College Station, TX, USA)
and differential expression among groups was evaluated with the
Wilcoxon rank-sum test. A p value lower than 0.05 was
considered statistically significant.
In vivo studies
Four–six week old SCID-NOD mice (Harlan Laboratories)
were housed under specific pathogen-free conditions. All proce-
dures involving animals were performed in accordance with
national and international current regulations (D.l.vo 27/01/1992,
n.116, European Economic Community Council Directive 86/
609, OJL 358, December 1, 1987). Thirty animals were injected s.
c. in the left flank with 5 £ 106 SU-DHL-4 cells and separated in
two groups of 15 mice each. The same protocol was applied to
30 SCID/NOD mice injected s.c. in the left flank with 2.5 £ 106
Oci-Ly8 cells. The first group of mice was treated with 3 weekly
doses of rhIL-17A (1 mg/mouse per dose) starting one day after
injection of tumor cells. The second group was treated with PBS
(controls) following the same time schedule. The concentration of
IL-17A to be injected in vivo was chosen on the basis of previous
studies.1 Twenty days after tumor cell inoculation, mice were killed
since signs of poor health such as enlarging tumor masses and pres-
ence of ruffled fur, became evident and autopsies were carried out.
Tumor masses were explanted, measured as described 49 and used
for following ex vivo analyses.
Morphologic and immunohistochemical analyses on mouse
tissue
Tumor masses formed by SU-DHL-4 cells were subjected to
morphological and immunohistochemical analyses, as
described.49,50 Formalin-fixed, paraffin-embedded sections were
incubated for 30 min with rabbit anti-human/mouse laminin
(Biogenex) Abs or with rat anti-mouse CD31 (clone SZ31; Dia-
nova). CD31 positive vessels were counted in eight randomly
chosen fields under a microscope £400 field (£40 objective and
£10 ocular lens; 0.180 mm2 per field). The rates of apoptotic
cells were determined by counting the number of TUNEL
positive cells/number of total cells in the viable neoplastic tissue
under a microscope £600 field (£60 objective and £10 ocular
lens; 0.120 mm2 per field).
Immunocomplexes were detected using the BondTM Polymer
Refine Detection Kit according to the manufacturer’s protocol
(Leica), then sections were counterstained with hematoxylin and
eosin. DNA fragmentation was detected in 4 mm tissue sections
by TUNEL staining with the ApopTag Plus Peroxidase In Situ
Apoptosis Kit (Millipore, Billerica, MA, USA), according to the
manufacturer’s protocol.
Angiogenesis PCR-Array
RNA was extracted from mouse tumors using Qiagen (Hil-
den) kit, reverse transcribed and processed using human or
mouse Angiogenesis RT2 PCR Array (SABioscience), as
described. 49 PCR was performed on ABI Prism 7700 Sequence
Detector (Applied Biosystems).
CAM assay
CAM assay was carried out as previously reported 49 to inves-
tigate the angiogenic activity of IL-17A. The technique is detailed
in the Supplemental Methods online.
Statistical analysis
Differences in tumor volume, chemotaxis, RGS16 expression,
apoptotic and proliferating cells and NF-kBp65 phosphorylation
were calculated using Mann–Whitney test comparing two indepen-
dent samples, with 99% confidence interval (GraphPad Prism 3).
All statistical tests were two tailed. A p value lower than 0.05 was
considered statistically significant. Quantitative studies of stained
sections were performed independently by two pathologists in a
blind fashion. Differences in the number of apoptotic cells and
tumor microvessels in immunohistological studies were evaluated
by Student’s t test. All statistical tests were two-tailed and a p value
lower than 0.05 was considered statistically significant.
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